Hodgkin's Lymphoma: Prognostic Value of the Kinetic of Decrease of 5 Cytokines Concentration During Treatment
To evaluate the decrease of cytokines concentration with a prognostic value as markers of
response, the dosage of TARC, IL-6, IL1-RA, sCD30 and TNFR1 will be performed during
treatment at :diagnosis, cycle 1 day 15, cycle 2 Day 1, cycle 3 Day 1, Day 1 of
consolidation (Cycle 5 day 1 or before radiotherapy) and evaluation of end of treatment.
an early follow-up with a dosage of cytokines will be performed 3 months after the end of
An evaluation for Event Free Survival will be done at 3 years from diagnosis.
Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic
Decrease of cytokines concentration TARC, IL-6, IL1-RA, sCD30, TNFR1) as markers of response during treatment and during early follow-up in Hodgkin's disease
evaluate the decrease of cytokines concentration with a prognostic value (TARC, IL-6, IL1-RA, sCD30, TNFR1) as markers of response during treatment (At Cycle 1 Day 15 of chemotherapy,Cycle 2 Day 1, cycle 3 Day 1, Cycle 5 Day 1 or Day 1 of Radiotherapy, 1 month after the end of treatment) , and during early follow-up (3 months after the end of treatment) in patients with Hodgkin's disease
90 days after end of treatment
Aspasia STAMATOULLAS, MD
CENTRE HENRI BECQUEREL-Rouen
France: Afssaps - Agence française de sécurité sanitaire des produits de santé (Saint-Denis)